Lp(a): 101.1 percentage-point reduction vs placebo · 36 weeks
225 mg every 12 weeks
Established ASCVD and Lp(a)>150 nmol/L
Placebo-adjusted mean percentage change in Lp(a).
Safety context
Any adverse event: 84% vs 83%; serious events: 11% vs 15% (selected dose/placebo). Injection-site pain was the common treatment-related reaction.
Limitations: The adjusted reduction exceeds 100% because placebo increased; it does not mean a negative Lp(a) level. Event reduction is a separate question.
Status in this atlas: Current approval status is not summarized in this therapy record. A trial phase or a brand name does not establish approval for this use.
Suppresses apolipoprotein(a) production by targeting LPA messenger RNA in liver cells.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
The molecule
Synthetic double-stranded siRNA conjugated to N-acetylgalactosamine for delivery to hepatocytes.
Small interfering RNA
Olpasiran
Synthetic double-stranded siRNA conjugated to N-acetylgalactosamine for delivery to hepatocytes.
Shown: GalNAc-conjugated siRNA (AMG 890).
Architecture and molecular target are verified in the original discovery/phase 1 paper. No exact whole-drug atomic model has been verified for this bundle; no generic nucleic-acid model is supplied.
A next milestone is not summarized for this therapy. This does not mean development has ended.
Development history4 selected milestones
Olpasiran · compound history across indications
Selected sourced milestones, not a complete development history. Dates distinguish study starts, publications, announcements and approvals; the first listed date is not necessarily when development began.
Study start
First human AMG 890 study starts
The registry records the actual start of a randomized, placebo-controlled phase 1 study of AMG 890, later named olpasiran, assessing safety, pharmacokinetics and Lp(a) lowering.
Nature Medicine reported the discovery program and phase 1 human results. Single doses produced substantial Lp(a) reductions lasting several months, supporting repeated-dose testing.
The plotted phase 2 trial reported large, dose-dependent Lp(a) reductions at week 36 in patients with established atherosclerotic cardiovascular disease. Cardiovascular benefit was not established by this biomarker trial.
The registry records the actual start of the phase 3 study comparing olpasiran with placebo for coronary death, myocardial infarction or urgent coronary revascularization in patients with ASCVD and elevated Lp(a).